期刊
FASEB JOURNAL
卷 20, 期 12, 页码 2027-2035出版社
FEDERATION AMER SOC EXP BIOL
DOI: 10.1096/fj.05-5404com
关键词
VEGF; KDR; neovascularization
资金
- NCI NIH HHS [R01 CA106582-02, P01 CA82713-06] Funding Source: Medline
- NCRR NIH HHS [U54 RR020843-02] Funding Source: Medline
Orlistat, an antiobesity drug, is cytostatic and cytotoxic to tumor cells (1). The antitumor activity of orlistat can be attributed to its ability to inhibit the thioesterase domain of fatty acid synthase (FAS). The objective of the present study was to test the effect of orlistat on endothelial cell proliferation and angiogenesis. Orlistat inhibits endothelial cell FAS, blocks the synthesis of fatty acids, and prevents endothelial cell proliferation. More significantly, orlistat inhibits human neovascularization in an ex vivo assay, which suggests that it may be useful as an antiangiogenic drug. The mechanism of these effects can be traced to the fact that orlistat prevents the display of the vascular endothelial growth factor (VEGF) receptor (VEGFR2/KDR/Flk1) on the endothelial cell surface. Thus, orlistat is an antiangiogenic agent with a novel mechanism of action.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据